Marex Group’s Metagenomi Therapeutics MGX Stock Holding History

Marex Group’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,000	Closed	-$34.5K	–	1165
2025 Q3	$34.5K	Hold	15,000	–	–	﹤0.01%	811
2025 Q2	$22.2K	Hold	15,000	–	–	﹤0.01%	619
2025 Q1	$20.4K	Hold	15,000	–	–	﹤0.01%	663
2024 Q4	$54.1K	Buy	+15,000	New	+$36.2K	﹤0.01%	638

Other funds holding MGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marex Group's MGX Position: Q4 2025 in Review

Marex Group sold out of Metagenomi Therapeutics (MGX) in Q4 2025, closing a stake of 15,000 shares — an estimated $34.5K sold.

Marex Group first reported a position in MGX in Q4 2024 and held it in 4 quarters. The position peaked at $54.1K in Q4 2024. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

Marex Group reported no remaining Metagenomi Therapeutics position as of Q4 2025 after selling out during the quarter.
Marex Group sold 15,000 Metagenomi Therapeutics shares in Q4 2025, an estimated $34.5K.
Marex Group first reported a position in Metagenomi Therapeutics in Q4 2024 and held it in 4 quarters.
Marex Group's Metagenomi Therapeutics position peaked at $54.1K in Q4 2024.
56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Marex Group's 13F filing for Q4 2025, filed 12 Feb 2026.